AG joins $71 million agreement to stop off-label medication marketing
SEATTLE — Attorney General Bob Ferguson today joined 47 other state attorneys general and the District of Columbia in a $71 million agreement resolving allegations that Amgen, Inc. unlawfully promoted two medications for uses and doses not approved by the federal Food and Drug Administration.
Amgen produces Aranesp and Enbrel. Aranesp is used to treat certain types of anemia by stimulating bone marrow to produce red blood cells. Enbrel is used to treat a number of conditions, including plaque psoriasis.